Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
about
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.Debunking the Delusion That Precision Oncology Is an Illusion.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
P2860
Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@en
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@nl
type
label
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@en
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@nl
prefLabel
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@en
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@nl
P2093
P2860
P356
P1433
P1476
Activity of c-Met/ALK Inhibito ...... Harboring EWSR1-CREB1 Fusion.
@en
P2093
Alexa B Schrock
Behrang Amini
Daniel Spritz
David L Stockman
James H Suh
Jeffrey S Ross
Jo-Anne Vergilio
Julia A Elvin
Kyle Gowen
Maria Zarzour
P2860
P304
P356
10.1159/000449204
P577
2016-10-21T00:00:00Z